Home  About us  Contact
 

Maintenance Insomnia (maintenance + insomnia)

Distribution by Scientific Domains
Medical Sciences75%

Kinds of Maintenance Insomnia

  • sleep maintenance insomnia
    		•

    Selected Abstracts

    Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate

    HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 1 2008
    Thomas Roth
    Abstract Objectives Buffered low-dose sublingual transmucosal zolpidem lozenge hemitartrate (ST zolpidem) is being developed for the treatment of middle-of-the-night insomnia. The objective of this double-blind placebo-controlled cross-over study (n,=,24) was to evaluate the pharmacokinetics (PK) and daytime-sedative profile of 1.0, 1.75, and 3.5,mg dose of the formulation. Methods Daytime sedation was measured pre-dose and up to 5,h post-dose objectively by the Digit Symbol Substitution Test (DSST) and subjectively using the Visual Analog Scale (VAS). Blood samples for PK assessment was collected pre-dose and up to 12,h post-dose. Results The 1.75 and 3.5,mg, but not the 1,mg, ST zolpidem produced significant sedation versus placebo within 20,min of dosing which lasted for up to 3,h. Zolpidem from the formulation was rapidly absorbed and reached maximum plasma concentrations within 38,min of dosing, however the half-life was independent of the dose and side effects were consistent with the known pharmacology of the drug. Conclusions ST zolpidem produced rapid, short duration of sedation and the effect was consistent with its PK profile. This novel low-dose formulation of zolpidem may provide clinicians and patients with a prn option for the management of sleep maintenance insomnia. Copyright © 2007 John Wiley & Sons, Ltd. [source]

    Indiplon: the development of a novel therapy for the treatment of sleep onset and sleep maintenance insomnia

    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, Issue 6 2007
    A. Lankford
    Summary Indiplon is a novel non-benzodiazepine sedative-hypnotic that modulates the GABAA receptor complex. It appears to be more selective for the ,1-receptor subunit, associated with sedation, than other hypnotics. Two different formulations of indiplon have been developed: an immediate release (IR) version targeting sleep onset insomnia and a modified release (MR) version addressing sleep maintenance insomnia. Early results from clinical trials indicate that both formulations are well tolerated and effective at improving both objective and subjective measures of sleep. As of May 2006 indiplon-IR has been provisionally approved for use in the US market and discussions are continuing with the FDA regarding the MR formulation. [source]

    Fluvoxamine and sleep disturbances in posttraumatic stress disorder

    JOURNAL OF TRAUMATIC STRESS, Issue 3 2001
    Thomas C. Neylan
    Abstract This study assesses the efficacy of fluvoxamine treatment on different domains of subjective sleep quality in Vietnam combat veterans with chronic posttraumatic stress disorder (PTSD). Medically healthy male Vietnam theater combat veterans (N = 21) completed a 10-week open label trial. Fluvoxamine treatment led to improvements in PTSD symptoms and all domains of subjective sleep quality. The largest effect was for dreams linked to the traumatic experience in combat. In contrast, generic unpleasant dreams showed only a modest response to treatment. Sleep maintenance insomnia and the item "troubled sleep" showed a large treatment response, whereas sleep onset insomnia improved less substantially. These therapeutic benefits contrast with published reports that have found activating effects of Selective Serotonin Reuptake Inhibitors on the sleep electroencephalogram. [source]